GLP-1 Drugs and PCOS: Insulin Resistance, Fertility, and What the Evidence Shows
Polycystic ovary syndrome is the most common hormonal disorder in women of reproductive age, affecting approximately 8–13% of women worldwide. Its core pathophysiology — insulin resistance driving androgen excess and ovarian dysfunction — is directly addressed by the mechanism of GLP-1 receptor agonism.
This article awaits medical-reviewer signoff.
Why GLP-1s are relevant to PCOS
PCOS is characterised by three main features:
- Hyperandrogenism: excess androgen hormones (testosterone, DHEAS) causing irregular periods, hirsutism, acne
- Ovarian dysfunction: irregular or absent ovulation, polycystic ovary appearance on ultrasound
- Insulin resistance: present in 50–70% of PCOS patients regardless of weight, but more severe in those with obesity
Insulin resistance is the upstream driver: high insulin levels stimulate the ovaries to produce more androgens, which disrupt follicular development and ovulation. This creates a cycle where insulin resistance worsens androgen excess, which worsens insulin resistance.
GLP-1's entry point: GLP-1 therapy improves insulin sensitivity — both through the weight loss it produces (fat tissue improvement) and through direct effects. Improved insulin sensitivity reduces the hyperinsulinaemia driving androgen overproduction. This breaks the cycle at a mechanistic level.
What the clinical evidence shows
Published PCOS studies with GLP-1s (primarily liraglutide and semaglutide, as these have the most evidence; tirzepatide PCOS data is emerging):
| Marker | Direction of effect |
|---|---|
| Body weight | Significant reduction |
| BMI | Reduction |
| Fasting insulin | Reduction |
| HOMA-IR (insulin resistance index) | Improvement |
| Total testosterone | Reduction |
| DHEAS | Reduction or no change |
| SHBG (sex hormone binding globulin) | Increase (reduces free testosterone) |
| Menstrual regularity | Improvement in most studies |
| AMH (anti-Müllerian hormone) | Improvement in some studies |
| Ovulation rate | Improvement in anovulatory patients in several studies |
Compared to metformin
Several studies have compared liraglutide or semaglutide to metformin in PCOS patients. Key findings:
- GLP-1s consistently produce greater weight loss than metformin
- Improvements in testosterone and androgen markers are comparable or greater with GLP-1s
- Menstrual cycle regularisation appears in both treatments
- GLP-1 therapy produces more significant improvements in metabolic markers (insulin resistance, lipids, blood pressure)
This does not make GLP-1s uniformly superior to metformin for PCOS — metformin is lower cost, has a longer evidence record in PCOS, and is generally better tolerated. The clinical decision depends on individual presentation, weight, metabolic markers, and access.
The fertility dimension
The fertility-restoration dynamic in PCOS is a clinically important consideration at GLP-1 initiation.
The restoration mechanism: In PCOS patients who are anovulatory (not ovulating due to hyperandrogenism and insulin resistance), improving insulin resistance can restore ovarian cyclicity. GLP-1 therapy has been shown to increase ovulation rates in previously anovulatory PCOS patients in several studies.
The pregnancy implication: A PCOS patient who starts GLP-1 therapy and was previously anovulatory may begin ovulating without expecting to — and is now capable of conception. This is not a problem with GLP-1 therapy; it is a benefit. But it means effective contraception discussion is important at initiation for patients who do not wish to become pregnant.
For patients who do want to conceive: GLP-1 therapy's metabolic improvements can support fertility in PCOS. Some practitioners use a structured approach: GLP-1 therapy to restore insulin sensitivity and ovarian function, then stop the drug with the 2-month pre-conception lead time per the label, then attempt conception. This requires coordinated care between the prescriber and a reproductive endocrinologist or fertility specialist.
Practical considerations for PCOS patients on GLP-1s
Weight goals: Not all PCOS patients are obese. GLP-1s can benefit PCOS patients with a normal BMI if insulin resistance is present, though the evidence base is stronger for overweight/obese populations.
Acne and hirsutism: Improvements in androgen markers can reduce acne and slow hirsutism progression, but these effects take time (months) and may not fully resolve without additional treatment.
Period changes: Menstrual regularity often improves on GLP-1 therapy in PCOS, though not universally. Irregular cycles during early treatment may reflect the metabolic transition rather than a problem.
Other PCOS treatments: GLP-1s are not a replacement for oral contraceptives (for cycle regulation and androgen management) or for inositol, spironolactone, or other PCOS-specific treatments. They address the metabolic component; the full PCOS treatment picture may include other interventions.
Editorial note: This article awaits medical-reviewer signoff. PCOS management is highly individualised. Discuss GLP-1 therapy and fertility implications with your prescriber and, for fertility-specific planning, a reproductive endocrinologist.
Frequently asked questions
Can GLP-1 drugs help with PCOS?
GLP-1 therapy improves several core PCOS manifestations in published studies: insulin sensitivity, body weight, androgen markers (testosterone, DHEAS), menstrual regularity, and fertility markers. GLP-1s are not FDA-approved specifically for PCOS, but their use is supported by evidence in this population. Discuss GLP-1 therapy in the context of your specific PCOS presentation with your prescriber. This page awaits medical reviewer signoff.
Is semaglutide better than metformin for PCOS?
Metformin and GLP-1s address insulin resistance through different mechanisms. Metformin inhibits hepatic glucose production and is first-line for insulin resistance in PCOS. Published comparisons suggest GLP-1s produce greater weight loss and similar or greater improvements in androgen markers compared to metformin in PCOS populations. Whether GLP-1 monotherapy, metformin monotherapy, or combination therapy is appropriate depends on the individual's clinical picture. Discuss with your prescriber.
Can GLP-1 therapy restore fertility in PCOS?
GLP-1 therapy has been shown to improve ovulation rates in some anovulatory PCOS patients by improving insulin resistance and reducing androgen excess. Women who were not previously ovulating may resume ovulation on GLP-1 therapy. This means some PCOS patients on GLP-1s become pregnant without planning for it. Contraception discussion and pregnancy planning are important at GLP-1 initiation for reproductive-age PCOS patients.
Should I stop my GLP-1 if I want to get pregnant with PCOS?
Yes. GLP-1 labels recommend stopping at least 2 months before planned conception. If GLP-1 therapy has restored ovulation in a previously anovulatory patient, pregnancy is now possible — stop the drug with the 2-month lead time before trying to conceive. Discuss timing and the role of GLP-1 in your fertility plan with your prescriber and, if appropriate, a reproductive endocrinologist.